Another study identified SOX9 as an independent risk factor for both RFS and overall survival (OS) in HCC patients treated with sorafenib, as it enhances sorafenib resistance through the modulation of ABCG2 [11]. The gene discussed is SOX9; the disease is hepatocellular carcinoma.